eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference
October 26, 2023 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, will present new data and host a...
eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
October 11, 2023 11:05 ET
|
eGenesis
- Proof of concept study resulted in life-supporting organ function and recipient survival of over two years - Donor kidneys carrying human transgenes resulted in longer survival time CAMBRIDGE,...
eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant
June 13, 2023 05:00 ET
|
eGenesis
CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, today announced the publication of a...
eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023
June 05, 2023 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American...
eGenesis Announces Knut Niss as Chief Technology Officer
January 24, 2023 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss,...
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
January 09, 2023 08:30 ET
|
eGenesis
-Agreement leverages Eledon’s investigational anti-CD40L antibody, tegoprubart, as part of eGenesis’ immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients- ...
eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer
April 19, 2022 08:30 ET
|
eGenesis
Dr. Curtis succeeds Paul Sekhri, who remains on Board of Directors Reflects company’s focus on advancement of portfolio toward clinical development CAMBRIDGE, Mass., April 19, 2022 (GLOBE...
eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer
April 04, 2022 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs and cells, today announced the appointment of Eliezer...
eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model
March 09, 2022 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing company developing human-compatible (HuCo™) organs and cells, today announced the initiation of a research collaboration...
eGenesis Appoints Bradford Smith as an Independent Member of Its Board of Directors
June 09, 2021 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs and cells, today announced the appointment of...